Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cortexyme Inc (NQ: CRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cortexyme Inc

< Previous 1 2 3 4 5 Next >
Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate
Cortexyme Inc (NASDAQ: CRTX) has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease. COR803 is a novel patent-pending small... 
Via Benzinga
Exposures COVID-19
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
Cortexyme to Present New Data at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Host Symposium at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval
Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval. 
Via Investor's Business Daily
Exposures Product Safety
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at Investor Conferences in June 2021
From Cortexyme, Inc.
Via Business Wire
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
Cortexyme Provides Business Update and Reports First Quarter 2021 Results
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
From Cortexyme, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.